Phase 2 Study of BA058 Transdermal Delivery in Postmenopausal Women With Osteoporosis



Status:Completed
Conditions:Osteoporosis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:Any
Updated:2/4/2013
Start Date:August 2012
End Date:August 2013
Contact:Louis Brenner, MD
Email:info@radiuspharm.com
Phone:617-551-4700

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of BA058 Administered Via a Coated Transdermal Microarray Delivery System (BA058 Transdermal) in Healthy Postmenopausal Women With Osteoporosis


To determine the clinical safety and efficacy of BA058 Transdermal in otherwise healthy
postmenopausal women with osteoporosis as assessed by changes in bone mineral density (BMD)
and serum markers of bone metabolism when compared to Transdermal Placebo and BA058
Injection for 6 months of treatment.


Inclusion Criteria:

- Postmenopausal woman, less than 85 years old.

- BMD T-score ≤ -2.5 of spine or hip (femoral neck) or ≤ -2.0 with previous fracture
(within 5 years).

- Normal physical exam, vital signs, electrocardiogram (ECG) and medical history.

- Laboratory tests within the normal range including serum calcium, Vit D, PTH(1-84),
serum phosphorus and alkaline phosphatase.

Exclusion Criteria:

- BMD T-score ≤ -5.0 at the lumbar spine or hip.

- History of bone disorders (e.g., Paget's disease) other than postmenopausal
osteoporosis.

- Significantly impaired renal function.

- History of any cancer.
We found this trial at
3
sites
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Decatur, GA
Click here to add this to my saved trials